Result
Safety · Primary, pre-specified · Efficacy
Effect as reported: [object Object]
Location in the source: results
PRIMARY · Incidence of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) · unit: Participants · measured at: Up to Day 29 for Part 1 and Day 253 for Part 2 Part 1 - AXER-204 - 3 mg: 5
Study
NCT03989440/brief_summary
human Human · Open label · Uncontrolled · Outside our vocabulary · AIS not reported
Participants actually studied: 52
No dataNothing has been recorded here yet. This is not a zero.
What this result says about which claim
Nothing has been recorded here yet.
This map holds only what has been read and checked against a source, and nothing has been recorded for this section. Empty here means exactly that — not zero, and not a fault in the page.